Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters

Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived allor...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Sarah, Ruggeri, Loredana, Dan, Elisa, Rizzi, Simonetta, Sinigaglia, Barbara, Ocadlikova, Darina, Bontadini, Andrea, Giudice, Valeria, Urbani, Elena, Ciardelli, Sara, Sartor, Chiara, Cristiano, Gianluca, Nanni, Jacopo, Zannoni, Letizia, Chirumbolo, Gabriella, Arpinati, Mario, Lewis, Russell E., Bonifazi, Francesca, Marconi, Giovanni, Martinelli, Giovanni, Papayannidis, Cristina, Paolini, Stefania, Velardi, Andrea, Cavo, Michele, Lemoli, Roberto M., Curti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841588/
https://www.ncbi.nlm.nih.gov/pubmed/35173709
http://dx.doi.org/10.3389/fimmu.2021.804988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841588/
https://www.ncbi.nlm.nih.gov/pubmed/35173709
http://dx.doi.org/10.3389/fimmu.2021.804988

Ejemplares similares